Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF -Mutant Melanoma

10 Jan 2019

Abstract excerpt

Abstract Purpose: BRAF V600E and V600K melanomas have distinct clinicopathologic features, and V600K appear to be less responsive to BRAFi±MEKi. We investigated mechanisms for this and explored whether genotype affects response to immunotherapy. Experimental Design: Pretreatment formalin-fixed paraffin-embedded tumors from patients treated with BRAFi±MEKi underwent gene expression profiling and DNA sequencing....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cutaneous Melanoma Detection and Management
Share to Melanoma and MAPK Pathways
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30630828
DOI: 10.1158/1078-0432.ccr-18-1680

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF -Mutant MelanomaPMID 30630828Read ↗

Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience.Semantic proximity Read ↗

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous MelanomaSemantic proximity Read ↗

Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.Semantic proximity Read ↗

Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary MelanomasSemantic proximity Read ↗

Management of V600E and V600K BRAF-Mutant Melanoma.Semantic proximity Read ↗

Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.Semantic proximity Read ↗

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.Semantic proximity Read ↗

Targeted Therapy in Advanced Melanoma With Rare BRAF MutationsSemantic proximity Read ↗

BRAF V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes.Semantic proximity Read ↗

Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant TumorsSemantic proximity Read ↗

Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumorsSemantic proximity Read ↗

Dissecting the Spectrum of Rare BRAF Mutations in Melanoma: A Nation-Wide Study by the Italian Melanoma Intergroup (IMI).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.